• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by IQVIA Holdings Inc.

    2/14/24 4:11:54 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $IQV alert in real time by email
    SC 13G 1 formsc13g-02142024_090247.htm FORM schedule-13g


     
     


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934


     
    IQVIA Holdings Inc.
    (Name of Issuer)
    Common Stock, par value $0.01 per share
    (Title of Class of Securities)
    46266C105
    (CUSIP Number)
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [ x ] Rule 13d-1(b)

    [   ] Rule 13d-1(c)

    [   ] Rule 13d-1(d)



    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.


    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     
     


     
    CUSIP No. 46266C105
      (1)   

    Names of Reporting Persons/ I.R.S. Identification Nos. of Above Persons (Entities Only)

     

        Harris Associates L.P.

        04-3276558

      (2)  
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)  
    (b)  
      (3)  

    SEC Use Only

     

      (4)  

    Citizenship or Place of Organization

     

        US

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

       (5)    

    Sole Voting Power

     

        7,848,356

       (6)   

    Shared Voting Power

     

        0

       (7)   

    Sole Dispositive Power

     

        9,747,869

       (8)   

    Shared Dispositive Power

     

        0

    (9)

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

        9,747,869

    (10)

     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares   [   ]

     

        (See Instructions)

    (11)

     

    Percent of Class Represented by Amount in Row (9)

     

        5.34%

    (12)

     

    Type of Reporting Person (See Instructions)

     

        IA


    CUSIP No. 46266C105
      (1)   

    Names of Reporting Persons/ I.R.S. Identification Nos. of Above Persons (Entities Only)

     

        Harris Associates, Inc.

        04-3276549

      (2)  
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)  
    (b)  
      (3)  

    SEC Use Only

     

      (4)  

    Citizenship or Place of Organization

     

        US

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

       (5)    

    Sole Voting Power

     

        7,848,356

       (6)   

    Shared Voting Power

     

        0

       (7)   

    Sole Dispositive Power

     

        9,747,869

       (8)   

    Shared Dispositive Power

     

        0

    (9)

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

        9,747,869

    (10)

     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares   [   ]

     

        (See Instructions)

    (11)

     

    Percent of Class Represented by Amount in Row (9)

     

        5.34%

    (12)

     

    Type of Reporting Person (See Instructions)

     

        CO


    Item 1.
    (a) Name of Issuer
    IQVIA Holdings Inc.
    (b) Address of Issuer's Principal Executive Offices
    2400 Ellis Rd.
    Durham, North Carolina, 27703

    Item 2.
    (a) Name of Person Filing
    Harris Associates L.P. (""Harris")
    Harris Associates, Inc. ("General Partner")

    **Harris Associates, Inc., for itself and as General Partner
    (b) Address of Principal Business Office or, if none, Residence
    111 South Wacker Drive Suite 4600, Chicago, IL 60606
    (c) Citizenship
    See Item 4 on the cover page(s) hereto.
    (d) Title of Class of Securities
    Common Stock, par value $0.01 per share
    (e) CUSIP Number
    46266C105

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)
    [   ]
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)
    [   ]
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    [   ]
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    [   ]
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)
    [ x ]
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
    (f)
    [   ]
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
    (g)
    [   ]
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)
    [   ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [   ]
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [   ]
    Group, in accordance with §240.13d-1(b)(1)(ii)(J).

    Item 4.
    (a) Amount beneficially owned:
    By reason of advisory and other relationships with the person who owns the Shares, Harris may be deemed to be the beneficial owner of the shares specified in Item 9 on the cover page(s) hereto. Harris has been granted the power to vote Shares in circumstances it determines to be appropriate in connection with assisting its advised clients to whom it renders financial advice in the ordinary course of business, by either providing information or advice to the persons having such power, or by exercising the power to vote.
    (b) Percent of class:
    See Item 11 on the cover page(s) hereto.
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote
    See Item 5 on the cover page(s) hereto.
    (ii) Shared power to vote or to direct the vote
    See Item 6 on the cover page(s) hereto.
    (iii) Sole power to dispose or to direct the disposition of
    See Item 7 on the cover page(s) hereto.
    (iv) Shared power to dispose or to direct the disposition of
    See Item 8 on the cover page(s) hereto.

    Item 5. Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [   ]

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    N/A

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
    N/A

    Item 8. Identification and Classification of Members of the Group.
    Not applicable. This schedule is not being filed pursuant to Rule 13d-1(b)(1)(ii)(J) or Rule 13d-1(d).

    Item 9. Notice of Dissolution of Group.
    N/A

    Item 10. Certification.
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     


     
    SIGNATURES
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    Date:   February 14, 2024
    Harris Associates L.P.
    By: /s/ Rana J. Wright

    Name: Rana J. Wright
    Title: Chief Administrative Officer, General Counsel and Secretary


    Get the next $IQV alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IQV

    DatePrice TargetRatingAnalyst
    4/25/2025$160.00Buy → Hold
    HSBC Securities
    4/10/2025$170.00Overweight → Equal Weight
    Barclays
    2/3/2025Buy → Neutral
    BTIG Research
    12/20/2024$250.00Overweight
    Stephens
    10/14/2024Buy
    Redburn Atlantic
    9/4/2024$275.00Outperform
    RBC Capital Mkts
    7/24/2024$266.00 → $242.00Buy → Hold
    Jefferies
    6/6/2024$270.00Buy
    Goldman
    More analyst ratings

    $IQV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Patel Bhavik covered exercise/tax liability with 84 shares, decreasing direct ownership by 7% to 1,040 units (SEC Form 4)

    4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

    7/30/25 5:04:35 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Officer Cherofsky Keriann covered exercise/tax liability with 35 shares, decreasing direct ownership by 1% to 2,875 units (SEC Form 4)

    4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

    7/30/25 5:03:53 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 4 filed by Director Wims Morris Leslie

    4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

    7/28/25 5:04:18 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $IQV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IQVIA and Veeva Announce Long-term Clinical and Commercial Partnerships and Resolution of All Disputes

    Global partnerships to help customers improve clinical and commercial efficiency and effectiveness IQVIA (NYSE:IQV) and Veeva Systems (NYSE:VEEV) today announced global clinical and commercial partnerships and the complete resolution of all pending legal disputes. Under the terms of the long-term agreement, customers can use software, data, technology, and service offerings from Veeva and IQVIA together in a simple and efficient way. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250818883712/en/ The global partnerships make it easy for customers to work with IQVIA and Veeva in key areas including: Commercial: The companies

    8/18/25 9:00:00 AM ET
    $IQV
    $VEEV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Computer Software: Prepackaged Software
    Technology

    IQVIA Reports Second-Quarter 2025 Results

    Revenue of $4,017 million, up 5.3 percent year-over-year GAAP Net Income of $266 million, Adjusted EBITDA of $910 million GAAP Diluted Earnings per Share of $1.54, Adjusted Diluted Earnings per Share of $2.81 R&D Solutions quarterly bookings of $2.5 billion, representing a book-to-bill ratio of 1.12x R&D Solutions contracted backlog of $32.1 billion, up 5.1 percent year-over-year TAS Revenue of $1,628 million, up 8.9 percent year-over-year Repurchased $607 million of common stock in the quarter, over $1 billion year-to-date IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence

    7/22/25 7:00:00 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Healthcare's $110B AI Surge Is Picking Up Speed--and It's Just the Beginning

    USA News Group News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- As artificial intelligence reshapes the future of medicine, understanding how patients actually feel about it is becoming just as critical as the technology itself. A new study published in Nature introduced an "AI Affinity Score" to measure patient comfort with AI in clinical settings—showing that education level and region heavily influence acceptance. The findings suggest that personalizing AI integration based on patient attitudes can enhance care quality and satisfaction. That kind of insight is already guiding investor attention toward emerging opportunities in a secto

    7/8/25 9:34:00 AM ET
    $CI
    $GEHC
    $IQV
    Medical Specialities
    Health Care
    Medical Electronics
    Biotechnology: Commercial Physical & Biological Resarch

    $IQV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    IQVIA downgraded by HSBC Securities with a new price target

    HSBC Securities downgraded IQVIA from Buy to Hold and set a new price target of $160.00

    4/25/25 8:30:17 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    IQVIA downgraded by Barclays with a new price target

    Barclays downgraded IQVIA from Overweight to Equal Weight and set a new price target of $170.00

    4/10/25 8:49:29 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    IQVIA downgraded by BTIG Research

    BTIG Research downgraded IQVIA from Buy to Neutral

    2/3/25 8:45:01 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $IQV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Danhakl John G bought $255,740 worth of shares (1,275 units at $200.58) (SEC Form 4)

    4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

    2/7/25 7:03:59 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $IQV
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by IQVIA Holdings Inc.

    SCHEDULE 13G/A - IQVIA HOLDINGS INC. (0001478242) (Subject)

    8/14/25 4:28:07 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 10-Q filed by IQVIA Holdings Inc.

    10-Q - IQVIA HOLDINGS INC. (0001478242) (Filer)

    7/22/25 4:50:23 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    IQVIA Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)

    7/22/25 7:06:22 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $IQV
    Leadership Updates

    Live Leadership Updates

    View All

    IQVIA Appoints Richard Staub III President of Research & Development Solutions

    IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced it has appointed Richard Staub III, currently senior advisor to the Chairman and CEO, as president of its Research & Development Solutions (R&DS) business unit. Richard is a vastly experienced executive with 34 years in the life science sector and has held numerous senior executive roles across multiple contract research organizations. Richard previously served as the president of the R&DS business unit at IQVIA from 2016 to 2022. Under his exceptional leadership the R&DS business unit accelerated its growth, recorded consec

    9/25/23 8:01:00 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    IQVIA Appoints Dr. Christina Mack Chief Scientific Officer of Real World Solutions

    IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced the appointment of Dr. Christina Mack to serve as chief scientific officer for the company's Real World Solutions (RWS) business, effective July 7, 2022. Christina is succeeding Dr. Nancy Dreyer, who is retiring after nearly two decades with IQVIA. In this new role, Dr. Mack will be responsible for guiding the design and execution of innovative real-world studies, using advanced enriched evidence to enable faster decision-making and help advance clinical practices. Christina's career at IQVIA has included several leadership roles, all

    6/7/22 8:00:00 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    IQVIA Appoints Costa Panagos President of Research & Development Solutions (R&DS)

    IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and contract services to the life sciences industry, today announced the appointment of Costa Panagos, to serve as president of its Research & Development Solutions (R&DS) business unit. He is succeeding Richard Staub III, who is retiring after a successful career spanning more than three decades. Mr. Staub will remain with the company as a senior advisor to the CEO and continue supporting business development and client management activities. Mr. Panagos has more than 25 years of industry experience serving life sciences customers and managing contract research (CRO) organizati

    3/14/22 9:00:00 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $IQV
    Financials

    Live finance-specific insights

    View All

    IQVIA Reports Second-Quarter 2025 Results

    Revenue of $4,017 million, up 5.3 percent year-over-year GAAP Net Income of $266 million, Adjusted EBITDA of $910 million GAAP Diluted Earnings per Share of $1.54, Adjusted Diluted Earnings per Share of $2.81 R&D Solutions quarterly bookings of $2.5 billion, representing a book-to-bill ratio of 1.12x R&D Solutions contracted backlog of $32.1 billion, up 5.1 percent year-over-year TAS Revenue of $1,628 million, up 8.9 percent year-over-year Repurchased $607 million of common stock in the quarter, over $1 billion year-to-date IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence

    7/22/25 7:00:00 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    IQVIA to Announce Second-Quarter 2025 Results on July 22, 2025

    IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its second-quarter 2025 financial results before the market opens on Tuesday, July 22, 2025. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. T

    7/1/25 7:00:00 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    IQVIA Reports First-Quarter 2025 Results

    Revenue of $3,829 million GAAP Net Income of $249 million, Adjusted EBITDA of $883 million GAAP Diluted Earnings per Share of $1.40, Adjusted Diluted Earnings per Share of $2.70 R&D Solutions quarterly bookings of $2.1 billion, resulting in trailing-twelve-month bookings of $9.7 billion and a trailing-twelve-month book-to-bill ratio of 1.14x R&D Solutions contracted backlog of $31.5 billion, up 4.8 percent year-over-year TAS Revenue of $1,546 million, up 6.4 percent reported year-over-year and 7.6 percent at constant currency Operating Cash Flow of $568 million and Free Cash Flow of $426 million, up 13 percent year-over-year, representing 89 percent of Adjusted Net Income Rep

    5/6/25 7:00:00 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $IQV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by IQVIA Holdings Inc.

    SC 13G - IQVIA HOLDINGS INC. (0001478242) (Subject)

    8/15/24 7:57:23 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G filed by IQVIA Holdings Inc.

    SC 13G - IQVIA HOLDINGS INC. (0001478242) (Subject)

    2/14/24 4:11:54 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G/A filed by IQVIA Holdings Inc. (Amendment)

    SC 13G/A - IQVIA HOLDINGS INC. (0001478242) (Subject)

    1/25/24 4:59:33 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care